Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the
world's population show serological evidence of current or past infection. Hepatitis B virus is …

Background Prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)
involves neonatal immunoprophylaxis, with a birth dose of hepatitis B vaccine and immune …

Background Combating viral hepatitis is part of the UN Sustainable Development Goals
(SDGs), and WHO has put forth hepatitis B elimination targets in its Global Health Sector …

Background. The duration of protection in children and adults resulting from hepatitis B
vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and …

These guidelines for the treatment of persons who have or are at risk for sexually transmitted
diseases (STDs) were updated by CDC after consultation with a group of professionals …

HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three
injections over six months have demonstrated remarkable prophylactic efficacy in clinical …

Since 1982, safe and effective hepatitis B virus (HBV) vaccines have been commercially
available first derived from plasma of HBV infected persons and later from yeast cells using …

Asia accounts for 60% of the world population and half the global burden of cancer. The
incidence of cancer cases is estimated to increase from 6.1 million in 2008 to 10.6 million in …

Summary Background In sub-Saharan Africa, administration of hepatitis B virus (HBV) birth-
dose vaccines remains suboptimal. Evidence is scarce on whether African countries should …

Background The natural history of chronic HBV infection in sub-Saharan Africa is unknown.
Data are required to inform WHO guidelines that are currently based on studies in Europe …